ProShare Advisors LLC Purchases 26,021 Shares of Boston Scientific Corporation $BSX

ProShare Advisors LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 9.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 306,169 shares of the medical equipment provider’s stock after acquiring an additional 26,021 shares during the period. ProShare Advisors LLC’s holdings in Boston Scientific were worth $29,193,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in BSX. Envestnet Portfolio Solutions Inc. grew its holdings in Boston Scientific by 45.7% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 97,155 shares of the medical equipment provider’s stock valued at $9,256,000 after buying an additional 30,469 shares during the last quarter. WD Rutherford LLC lifted its holdings in shares of Boston Scientific by 53.4% during the fourth quarter. WD Rutherford LLC now owns 35,040 shares of the medical equipment provider’s stock worth $3,341,000 after buying an additional 12,191 shares during the last quarter. Requisite Capital Management LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $458,000. RiverFront Investment Group LLC increased its position in Boston Scientific by 0.7% during the fourth quarter. RiverFront Investment Group LLC now owns 21,308 shares of the medical equipment provider’s stock worth $2,032,000 after acquiring an additional 150 shares during the period. Finally, Passumpsic Savings Bank acquired a new position in Boston Scientific during the 4th quarter valued at $3,141,000. 89.07% of the stock is owned by institutional investors and hedge funds.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported positive pivotal results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter in the FRACTURE trial, meeting key safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The company plans to use the data to support a regulatory filing, which strengthens its cardiovascular pipeline and could expand future revenue. Article Title
• Positive Sentiment: The company announced a $2 billion accelerated share repurchase and a broader $5 billion buyback authorization, signaling confidence in its valuation and providing support for earnings per share over time. Article Title
• Positive Sentiment: Boston Scientific also invested $1.5 billion for an equity stake in MiRus, with an option tied to the company’s TAVR business, which could deepen BSX’s position in structural heart and create an additional growth path. Article Title
• Neutral Sentiment: Baird lowered its price target on BSX to $75 from $78 but kept an Outperform rating, suggesting analysts remain constructive even after revising near-term expectations lower. Article Title
• Neutral Sentiment: Other recent broker updates were mixed, with some firms reaffirming Buy ratings while Bank of America also trimmed its target, keeping the analyst backdrop supportive but not especially strong. Article Title
• Negative Sentiment: Some market commentary and fund commentary referenced BSX as having “weak results” or falling on that basis, which adds to the perception of recent pressure on the shares. Article Title

Boston Scientific Trading Down 0.4%

Shares of Boston Scientific stock opened at $56.59 on Thursday. Boston Scientific Corporation has a 12-month low of $52.52 and a 12-month high of $109.50. The stock has a market capitalization of $84.11 billion, a P/E ratio of 23.68, a price-to-earnings-growth ratio of 1.04 and a beta of 0.62. The company has a 50-day simple moving average of $62.46 and a 200 day simple moving average of $80.71. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BSX. Needham & Company LLC reaffirmed a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a research report on Monday. Barclays reduced their price objective on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. UBS Group decreased their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Bank of America lowered their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.